Geoffrey Gilmartin Net Worth

Geoffrey Gilmartin biography

Geoffrey S. Gilmartin M.D. serves as Chief Medical Officer of the Company. From January 2014 to August 2016, he held positions of increasing responsibility at AstraZeneca plc (NYSE:AZN), and most recently served as senior medical lead in global medicines development for the benralizumab Phase 3 program in severe asthma. From January 2011 to January 2014, he held positions of increasing responsibility at Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) including serving as medical lead for the Kalydeco® (ivacaftor) clinical development program, spearheading the initiation of Phase 3 trials to support label expansion studies for the drug. In addition to his leadership positions in the life sciences industry, Dr. Gilmartin is an attending physician in the intensive care unit at Beth Israel Deaconess Medical Center and formerly served as director of the BIDMC Sleep Disorders Center and on its pulmonary leadership team. Dr. Gilmartin received a B.A. in History from Dartmouth College, a M.D. from Brown University School of Medicine and a Master of Medical Science in clinical research from Harvard Medical School.

How old is Geoffrey Gilmartin?

Geoffrey Gilmartin is 52, he's been the Chief Medical Officer of Proteostasis Therapeutics Inc since 2019. There are 5 older and 3 younger executives at Proteostasis Therapeutics Inc. The oldest executive at Proteostasis Therapeutics Inc is Franklin Berger, 70, who is the Independent Chairman of the Board.

What's Geoffrey Gilmartin's mailing address?

Geoffrey's mailing address filed with the SEC is C/O PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON, MA, 02135.

Insiders trading at Proteostasis Therapeutics Inc

Over the last 9 years, insiders at Proteostasis Therapeutics Inc have traded over $9,140,918 worth of Proteostasis Therapeutics Inc stock and bought 12,301,024 units worth $94,383,855 . The most active insiders traders include M James Barrett, Llc Fmr e Bioventures Ltd Novartis Ag.... On average, Proteostasis Therapeutics Inc executives and independent directors trade stock every 36 days with the average trade being worth of $3,463,082. The most recent stock trade was executed by Enterprise Associates 12, L... on 26 November 2019, trading 1,283,919 units of PTI stock currently worth $3,222,637.

What does Proteostasis Therapeutics Inc do?

Proteostasis Therapeutics Inc executives and stock owners

Proteostasis Therapeutics Inc executives and other stock owners filed with the SEC include:

• Meenu Chhabra,
  President, Chief Executive Officer, Director
• Marija Zecevic,
  Chief Operating Officer
• Benito Munoz,
  Chief Scientific Officer
• Jeffery Kelly,
  Independent Director
• Emmanuel Dulac,
  Independent Director
• Kimberlee Drapkin,
  Independent Director
• Badrul Chowdhury,
  Independent Director
• David Arkowitz,
  Independent Director
• Geoffrey Gilmartin,
  Chief Medical Officer
• Franklin Berger,
  Independent Chairman of the Board
• Eric Rabinowitz,
  Director
• Co Plc Perrigo Holdings Ltd...,
  
• M James Barrett,
  Director
• Asset Management, Lp Chen B...,
  
• James M. Detore,
  See Remarks
• Llc Fmr,
  
• Brett R Hagen,
  Principal Accounting Officer
• Po Shun Lee,
  See Remarks
• Bioventures Ltd Novartis Ag...,
  
• Enterprise Associates 12, L...,
  
• Eric D Larson,
  See Remarks
• Helen M Boudreau,
  Director
• Enterprise Associates 12, L...,
  
• Sheila Wilson,
  Chief Operating Officer
• Christopher T Phd Walsh,
  Director
• Janet L Smart,
  See Remarks
• Christopher Mirabelli,
  Director
• Romeo Mirzac,
  Principal Accounting Officer
• Christopher Health Care Ven...,
  
• Conor M Walshe,
  Director